Hepatera
Web29 gen 2024 · "Hepatera", Ltd is a private biotechnology company, founded in 2011 with the goal to develop and launch into the Russian market innovative products for … WebEntry inhibitor Myrcludex B Hepatera/MYR GmbH Phase 2 cccDNA inhibitor Preclinical RNA silencers AROHBV Arrowhead Phase 1/2a ARB-1467 Arbutus Phase 2 ARB-1740 Arbutus Preclinical ALN-HBV Alnylam Phase 1/2 GSK 3228836 GlaxoSmithKline/Ionis Phase 1 Core protein/capsid inhibitors AL-3778 Alios/Johnson & Johnson Phase 1/2 ABI-H0731 …
Hepatera
Did you know?
WebFind company research, competitor information, contact details & financial data for HEPATERA LLC of Moscow, Moscow. Get the latest business insights from Dun & Bradstreet. Web20 ott 2024 · The roots should be trimmed, and the plants should be repotted in a moist potting medium that is kept well-watered during the spring. When dividing Hepatica, even …
Web28 nov 2024 · About Hepatera . Hepatera LLC is a private biotech company. The main activity of the company is the development of safe and effective drugs for the treatment of liver diseases for the Russian market. Web25 mag 2024 · Hepatera is Maxwell Biotech Venture Fund's Portfolio Company. The main activity of the company is the development of safe and effective drugs for the treatment …
Web“Hepatera”, LLC is a private Russian biotech company, that was founded in September 2011 and became a resident of the Biomedical Cluster at Skolkovo Innovation Center in December 2011. The company’s main goal is to develop and bring to the market innovative drugs for the prevention and treatment of liver diseases. WebIn 2007 graduated from I.M. Sechenov First Moscow State Medical University. Is engaged in research activities and medical analytics for more than 8 years. Has extensive experience in project management in the fields of commercial medicine, medical insurance, trade marketing and human resources. In 2014 joined «Maxwell Biotech Group» team and ...
An entry inhibitor that is being developed by MYR GmbH for the treatment of chronic HDV and HBV infections. Received its first approval on 31 July 2024 in the EU. Approved for use in chronic HDV infection in HDV RNA positive adult patients with compensated liver disease.
WebMOSCOW, Russia I December 12, 2012 I Hepatera, a Russian biotech company and part of Maxwell Biotech Venture Fund’s portfolio, has announced today the inclusion of the first three patients with chronic hepatitis B in the clinical trial phase Ib-IIa of Myrcludex B. Hepatera was founded in 2011 and is focused on the development of innovative … homemade disinfectant spray for pillowsWeb12 dic 2012 · MOSCOW--(BUSINESS WIRE)--Hepatera, a Russian biotech company and part of Maxwell Biotech Venture Fund’s portfolio, has announced today the inclusion of the first three patients with chronic ... homemade disinfecting wipes with paper towelsWeb6 mar 2014 · Hepatera was founded in 2011 with the goal of developing and launching innovative therapeutics for treatment of liver diseases into the Russian market. hind quarter menuWeb6 mar 2014 · A group of 48 patients infected with the hepatitis B virus (HBV) have been enrolled in the phase IIa clinical trial of Myrcludex B by Russian biotech company Hepatera Ltd. Hepatera is financed by ... hind quarter beef cuts chartWeb22 dic 2015 · PEG-INF-a is used for the treatment of chronic hepatitis delta. The study endpoints are virological response (HBsAg, hepatitis delta virus ribonucleic acid (HDV … homemade disinfectant room sprayhomemade distilled white vinegarWebHepatera LLC is a pharmaceutical company. The Company develops and markets drugs for the prevention and treatment of liver diseases. Terms of Service Trademarks Privacy … hind quarter cuts of beef